glp-1 attorney AWKO is proud to announce that Matthew Marcin has been appointed to the Plaintiffs' Executive Committee in two major MDLs: GLP-1 Receptor Agonists Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability GLP-1 Receptor Agonist Litigation: MDL

When someone applies for life insurance after losing weight on GLP-1 medications, underwriters see what looks like a healthy person with: Normal BMI Improved blood pressure Better cholesterol levels Lower HbA1c levels But here's the catch: Research from the landmark STEP 1 trial extension shows that participants regain approximately two-thirds of their prior weight loss within one year of stopping semaglutide (Wilding et al., 2022)

doi:10.2337/diabetes.52.2.380 34

What to do when your GLP-1 does not seem to be working You have been on the medication for weeks

PTM Analysis: PTM analysis of therapeutic peptides using MS identifies and characterizes modifications like phosphorylation, glycosylation, and acetylation

Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein